Skip to main content
. Author manuscript; available in PMC: 2013 Oct 28.
Published in final edited form as: J Control Release. 2012 Sep 6;163(2):161–169. doi: 10.1016/j.jconrel.2012.08.031

Fig. 1. MJ33 inhibits NOX mediated ROS.

Fig. 1

(a) Ang II actives PLA2 thereby releasing lysoPC from the plasma membrane resulting in NOX activation and release of ROS. (b) MJ33 inhibition of PLA2 activity prevents the release of lysoPC whereupon NOX2 does not translocate to the plasma membrane or release ROS. (c) PECAM targeted lipid nanoparticle structure with MJ33 cargo d) MJ33 (1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol, Li) MW 498.5 g/mol.

HHS Vulnerability Disclosure